CytomX Therapeutics Inc (NASDAQ: CTMX): Historical Performance And Trend

In the last trading session, 1.42 million shares of the CytomX Therapeutics Inc (NASDAQ:CTMX) were traded, and its beta was 1.15. Most recently the company’s share price was $0.80, and it changed around $0.04 or 5.90% from the last close, which brings the market valuation of the company to $64.24M. CTMX currently trades at a discount to its 52-week high of $5.06, offering almost -532.5% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 50.0% since then. We note from CytomX Therapeutics Inc’s average daily trading volume that its 10-day average is 1.51 million shares, with the 3-month average coming to 1.91 million.

CytomX Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended CTMX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.

CytomX Therapeutics Inc (NASDAQ:CTMX) trade information

Instantly CTMX has showed a green trend with a performance of 5.90% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.8250 on recent trading dayincreased the stock’s daily price by 3.03%. The company’s shares are currently down -22.14% year-to-date, but still up 12.96% over the last five days. On the other hand, CytomX Therapeutics Inc (NASDAQ:CTMX) is 31.76% up in the 30-day period. We can see from the shorts that 9.57 million shares have been sold at a short interest cover period of 8.13 day(s).

The consensus price target as assigned by Wall Street analysts is $3.46, which translates to bulls needing to increase their stock price by 76.88% from its current value. Analyst projections state that CTMX is forecast to be at a low of $3.25 and a high of $3.68.

CTMX Dividends

CytomX Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-05.

CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.15% of CytomX Therapeutics Inc shares, and 57.78% of them are in the hands of institutional investors. The stock currently has a share float of 58.45%. CytomX Therapeutics Inc stock is held by 82.0 institutions, with TANG CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 9.1799% of the shares, which is about 7.79 million shares worth $9.51 million.

JANUS HENDERSON GROUP PLC, with 7.4245% or 6.3 million shares worth $7.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.